News
KTTA
0.4500
-1.10%
-0.0050
Weekly Report: what happened at KTTA last week (0720-0724)?
Weekly Report · 2d ago
Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumors
PUBT · 07/21 15:53
Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026
Benzinga · 07/21 11:20
Pasithea Therapeutics posts press release on PAS-004 data presentation at ESMO 2026
PUBT · 07/21 11:03
Weekly Report: what happened at KTTA last week (0713-0717)?
Weekly Report · 07/20 09:22
New Strong Buy Stocks for July 20th
NASDAQ · 07/20 09:03
Pasithea publishes investor presentation on PAS-004 macrocyclic MEK inhibitor program in NF1 and solid tumors
PUBT · 07/15 21:38
Weekly Report: what happened at KTTA last week (0706-0710)?
Weekly Report · 07/13 09:22
Pasithea Therapeutics to attend B. Riley Securities Mind, Muscle & Vision Summit
PUBT · 07/08 11:06
Weekly Report: what happened at KTTA last week (0629-0703)?
Weekly Report · 07/06 09:23
Analysts’ Top Healthcare Picks: Pasithea Therapeutics Corp (KTTA), Xeris Pharmaceuticals (XERS)
TipRanks · 06/30 17:00
Pasithea Therapeutics announces updated data from PAS-004 trial
TipRanks · 06/30 11:15
Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2
Benzinga · 06/30 11:04
Pasithea reports positive interim Phase 1 data for PAS-004 in advanced solid tumors, expands dose escalation
PUBT · 06/30 11:03
PASITHEA THERAPEUTICS CORP - INITIATES PILOT FOOD EFFECT STUDY FOR PAS-4 PHARMACOKINETICS
Reuters · 06/30 11:00
PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 ADVANCED CANCER STUDY DATA DEMONSTRATING LONG-TERM SAFETY AND TOLERABILITY, AND DURABLE CLINICAL ACTIVITY IN MEK/BRAF-PRETREATED PATIENTS, PLUS PROTOCOL EXPANSION
Reuters · 06/30 11:00
Weekly Report: what happened at KTTA last week (0622-0626)?
Weekly Report · 06/29 09:22
Major Investor Quietly Boosts Stake in Pasithea Therapeutics
TipRanks · 06/23 02:06
Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000
PUBT · 06/22 14:31
Weekly Report: what happened at KTTA last week (0615-0619)?
Weekly Report · 06/22 09:24
More
Webull provides a variety of real-time KTTA stock news. You can receive the latest news about Pasithea Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.